106190 — High Tech Pharm Co Income Statement
0.000.00%
Last trade - 00:00- KR₩129bn
- KR₩116bn
- KR₩78bn
- 50
- 65
- 12
- 35
Annual income statement for High Tech Pharm Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 74,462 | 73,287 | 102,947 | 76,772 | 77,513 |
| Cost of Revenue | |||||
| Gross Profit | 1,314 | 3,078 | 7,779 | 12,843 | 19,487 |
| Selling / General / Administrative Expenses | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 77,819 | 73,699 | 98,020 | 66,683 | 61,955 |
| Operating Profit | -3,357 | -412 | 4,927 | 10,089 | 15,558 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -2,600 | -868 | 4,028 | 9,864 | 17,087 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -3,152 | -1,225 | 5,873 | 8,076 | 13,710 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -3,152 | -1,225 | 5,873 | 8,076 | 13,710 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -3,152 | -1,225 | 5,873 | 8,076 | 13,710 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -294 | -115 | 544 | 755 | 1,283 |
| Dividends per Share |